K-TOX — 2482473
Application number
2482473
Type(s)
Standard Characters
Category
Trademark
CIPO Status
FORMALIZED
TM5 status
LIVE/APPLICATION/
Awaiting Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
Filed
2026-06-17
Applicant
HUGEL, INC.
23, Geodudanji 1-gil, Dongnae-myeon,Chuncheon-si
Gangwon-do,
REPUBLIC OF KOREA
Agent
MCCARTHY TETRAULT LLP
SUITE 5300
TORONTO DOMINION BANK TOWER
TORONTO-DOMINION CENTRE
66 Wellington Street West, Suite 5300, Box 48
TORONTO
ONTARIO M5K1E6
Documents
Index headings
- K-TOX
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations for the treatment of muscle spasms; pharmaceutical preparations for treating dystonia; muscle relaxants; pharmaceutical preparations for animals for the treatment of aesthetic dermatology, orthopaedics, arthritis and ophthalmology; pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin namely, dermatitis, eczema, skin lesions, hyperkeratosis, skin irritations, rosacea, psoriasis, acne, wound scars; pharmaceutical preparations containing botulinum toxin; botulinum toxin; pharmaceutical preparations containing botulinum toxin for the treatment of wrinkles; pharmaceutical preparations containing botulinum toxin fragments for the treatment of wrinkles; pharmaceutical preparations for use in treating urogenital system diseases and conditions; bacterial toxins used for the treatment of cancer, blepharospasm, spasticity, dynamic equinus foot deformity, overactive bladder, benign masseter muscle hypertrophy, psychiatric disorders, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia, depression, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhidrosis, cerebral palsy, sports injuries, namely, injured and torn skin, muscle, ligaments and bone, tremors, namely, spasmodic smooth, striated and cardiac muscles, and for the relief of pain; pharmaceutical preparations for digestive system namely, for the treatment of peptic ulcer and gastroesophageal reflux disease; pharmaceutical preparations for treatment of skin conditions, namely acne, dryness and signs of skin aging; pharmaceutical preparations for treating neurological diseases and disorders, namely, Alzheimer's, Huntington's disease, cerebral palsy, myasthenia gravis, brain injury, spinal cord injury and seizure disorders, carpal tunnel syndrome, periodic limb movement disorder, epilepsy, radiculopathy, spinal muscular atrophy; ophthalmic preparations; anti-itch ointments for pharmaceutical purposes; chemical preparations for pharmaceutical purposes for the treatment of cancer, blepharospasm, spasticity, dynamic equinus foot deformity, overactive bladder, benign masseter muscle hypertrophy, psychiatric disorders, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia, depression, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhidrosis, cerebral palsy, sports injuries, namely, injured and torn skin, muscle, ligaments and bone, tremors, namely, spasmodic smooth, striated and cardiac muscles, and pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; pharmaceutical agents for treatment of the upper layers of the epidermis; drugs for medical purposes for the treatment of neurological disorders, namely, cancer, blepharospasm, spasticity, dynamic equinus foot deformity, overactive bladder, benign masseter muscle hypertrophy, psychiatric disorders, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia, depression, and for the treatment of muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhidrosis, cerebral palsy, sports injuries, namely, injured and torn skin, muscle, ligaments and bone, tremors, namely, spasmodic smooth, striated and cardiac muscles, and pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; biological preparations for medical and veterinary purposes for the treatment of aesthetic dermatology, orthopaedics, arthritis and ophthalmology; microorganisms for medical purposes namely, bacteria and fungi for the treatment of cancer, blepharospasm, spasticity, dynamic equinus foot deformity, overactive bladder, benign masseter muscle hypertrophy, psychiatric disorders, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia, depression, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhidrosis, cerebral palsy, sports injuries, namely, injured and torn skin, muscle, ligaments and bone, tremors, namely, spasmodic smooth, striated and cardiac muscles, and pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; biological tissue cultures of microorganisms for medical purposes; diagnostic chemical reagents for medical diagnostic use; pharmaceutical preparations for animals for the treatment of aesthetic dermatology, orthopaedics, arthritis and ophthalmology; adjuvants for medical purposes, namely, vaccines for human use; hyaluronic acid preparations for medical purposes for aesthetic treatments namely injectable for intradermal and subcutaneous application for facial and body skin tightening and smoothing; medicines for human purposes for the treatment of aesthetic dermatology, orthopaedics, arthritis and ophthalmology; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of orthopaedic disorders, namely hip dislocation, spinal column deformation, curvature of the spine namely scoliosis, lordosis, cyphosis; pharmaceutical preparations for alleviating wrinkles; injectable dermal filler; pain relief medicines for dental purposes; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, eczema, skin lesions, hyperkeratosis, skin irritations, rosacea, psoriasis, acne, wound scars; pharmaceutical preparations for treating skin disorders, namely for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations mainly based on hyaluronic acid for aesthetic treatments namely injectable for intradermal and subcutaneous application for facial and body skin tightening and smoothing; therapeutic drugs and agents for the treatment of excessive sweating, excessive eye blinking, blepharospasm, spasmodic torticollis, hemifacial spasm, muscle cramp, dynamic equinus foot deformity, strabismus, neuropathy pain, facial wrinkles, headache, pain, dystonia, urogenital system diseases and conditions, skin disorders.
Action History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2026-06-17 | ||
| Created | 2026-06-17 | ||
| Formalized | 2026-06-17 | ||
| Pre-Assessment Letter Sent | 2026-07-02 | Retired Goods or Services |